C4 Therapeutics, Inc.
CCCC
$1.54
$0.042.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -66.30% | 27.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -66.30% | 27.95% | |||
| Cost of Revenue | 2.12% | 34.04% | |||
| Gross Profit | -65.91% | -40.26% | |||
| SG&A Expenses | -11.85% | 21.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.65% | 30.37% | |||
| Operating Income | -33.51% | -31.72% | |||
| Income Before Tax | -39.63% | -39.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -40.16% | -39.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -40.16% | -39.23% | |||
| EBIT | -33.51% | -31.72% | |||
| EBITDA | -33.91% | -32.43% | |||
| EPS Basic | -38.22% | -37.59% | |||
| Normalized Basic EPS | -42.01% | -18.08% | |||
| EPS Diluted | -38.22% | -37.59% | |||
| Normalized Diluted EPS | -42.01% | -18.08% | |||
| Average Basic Shares Outstanding | 1.41% | 1.19% | |||
| Average Diluted Shares Outstanding | 1.41% | 1.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||